Our services span the entire lifecycle of product development and commercialisation, and can be adapted to suit small local trials or large global programs.
Serving US Federal and NGO clients.
Integrated services that cover planning, management, execution and analysis.
We have extensive experience in a broad range of therapeutic areas. Managing studies in all major geographies, we have established solid working relationships with the world’s leading investigators.
ICON has conducted hundreds of clinical studies in both solid and haematological tumours, including experience with CAR-T therapies.
Offering solutions that combine in-house expertise and proprietary innovative technology.
We develop integrated technologies to significantly enhance the efficiency and productivity of clients’ drug and device development programs.
Using data to design, simulate, and analyse adaptive clinical trials with ease.
Digital solutions that increase efficiency in clinical trials by driving site performance.
BioPharma companies and Medical Devices manufacturers face growing operational, regulatory and economic challenges. ICON provides analysis and key insights on these challenges, with practical advice and recommendations.
Remote monitoring and leveraging wearable devices and sensors in clinical trials.
The cost pressures on drug development are driving the search for savings. Results from an industry survey by ICON and Pharma Intelligence.
ICON regularly contributes thought leadership to industry media publications and conferences, and has been recognised as one of the world’s leading Contract Research Organisations through a number of high-profile industry awards.
31 July, 2018
On-demand webinar replays on a range of issues
Our mission is to help clients accelerate the development of drugs and devices that save lives and improve quality of life.
We are committed to exceeding the quality standards demanded by our clients, patients and regulatory authorities.
Partners Making a Difference.
The webinar explores new regulatory developments in both the US and Europe and how they are promoting a radical change to accelerate the approval of new medications for rare disease.
52:45
